[Skip to Navigation]
Sign In
March 26, 2020

JAMA Oncology—The Year in Review, 2019

Author Affiliations
  • 1Fred Hutchinson Cancer Research Center, University of Washington, Seattle
  • 2Editor, JAMA Oncology
JAMA Oncol. 2020;6(5):639-640. doi:10.1001/jamaoncol.2020.0134

JAMA Oncology had a very active year in 2019. The journal’s impact factor of 22.4 places it as one of the highest-ranking oncology journals. I thank our authors, peer reviewers, and readers for the significant contributions made to the journal this past year. The editorial board, our JAMA Oncology editors, and I are honored to have the opportunity to serve the oncology community by offering original, innovative, and timely scientific content that has a direct impact on researchers, clinicians, and the patients we serve.

Choosing manuscripts for the journal was rewarding but challenging. We received a total of 2980 manuscript submissions in 2019. These submissions to JAMA Oncology included 1743 Original Investigations, 66 Clinical Trial reports, 66 Meta-analyses, and 70 Reviews. In 2019, we published 419 total articles, including 119 Original Investigations, 31 Research Letters, 32 Viewpoints, 10 Reviews, and 5 Special Communications. I thank our authors for choosing JAMA Oncology. The quality of their articles is reflected in the more than 2.6 million views and downloads of JAMA Oncology articles last year.

In 2019, the overall acceptance rate was 13%. Our acceptance rate was 6% for Original Investigations, 35% for Clinical Trials reports, and 39% for Meta-analyses. We accepted 13% of Review articles, 11% of submitted Research Letters, 30% of Viewpoints, and 16% of Clinical Challenges. JAMA Oncology is indexed in PubMed/MEDLINE, Science Citation Index Expanded, Scopus, and other databases. More detailed statistics about our content are displayed in the Table.1-3

Table.  JAMA Oncology Statistics for 2019
JAMA Oncology Statistics for 2019

We are also very grateful to our global consortium of peer reviewers who contributed to the journal this year.4 I am pleased to acknowledge their contribution to JAMA Oncology by publishing the names of the more than 700 experts who completed a manuscript review in 2019. This group of renowned laboratory, clinical, quantitative, and statistical scientists provided comprehensive reviews of the submitted manuscripts in a median of just 14 days. The ability to rapidly review and return a decision on our submissions within a couple of weeks ensures that authors receive efficient service in reviewing their work and that those important findings are available to the oncology community as quickly as possible. We would not be able to provide this service without our expert peer reviewers and their commitment to providing prompt and high-quality reviews for the journal. We thank you!

Finally, I thank our readers. We provide our electronic table of contents of newly published material each week by email to more than 49 000 readers. If you currently do not receive the JAMA Oncology electronic table of contents by email, you can sign up at http://www.jamaoncology.com. We are proud to continue offering the most innovative, provocative, and timely research for scientists, clinicians, and trainees in the field of oncology worldwide. I encourage readers to stay involved with the journal by submitting Letters to the Editor and offering recommendations for new topics that you would like to see covered in future issues. Your suggestions make this interdisciplinary oncology journal dynamic and current.

We have truly enjoyed being involved in JAMA Oncology’s continued success this year and look forward to the year ahead. We could not have done it without you. I invite all of our readers to follow us on Twitter @JAMAOnc or friend JAMA Oncology on Facebook. We will keep you up to date on the most important discoveries influencing cancer care.

Back to top
Article Information

Corresponding Author: Mary L. (Nora) Disis, MD, Fred Hutchinson Cancer Research Center, University of Washington, 850 Republican St, Brotman 221, Box 358050, Seattle, WA 98195-8050 (ndisis@uw.edu).

Published Online: March 26, 2020. doi:10.1001/jamaoncol.2020.0134

Conflict of Interest Disclosures: None reported.

Garcia-Murillas  I, Chopra  N, Comino-Méndez  I,  et al.  Assessment of molecular relapse detection in early-stage breast cancer.   JAMA Oncol. 2019;5(10):1473-1478. doi:10.1001/jamaoncol.2019.1838PubMedGoogle ScholarCrossref
Yang  JJ, Yu  D, Xiang  Y-B,  et al.  Association of dietary fiber and yogurt consumption with lung cancer risk: a pooled analysis.   JAMA Oncol. Published online October 24, 2019. doi:10.1001/jamaoncol.2019.4107PubMedGoogle Scholar
Liu  P-H, Wu  K, Ng  K,  et al.  Association of obesity with risk of early-onset colorectal cancer among women.   JAMA Oncol. 2019;5(1):37-44. doi:10.1001/jamaoncol.2018.4280PubMedGoogle ScholarCrossref
 JAMA Oncology peer reviewers in 2019.   JAMA Oncol. Published online March 26, 2020. doi:10.1001/jamaoncol.2020.0100Google Scholar